Inferra AI / Company / OPK

Opko Health, Inc.

OPK · Health Care

Last earnings Jul 27, 2026

Key results

Revenuequarter

$156.8 million

Second Quarter Financial Results • Consolidated: Consolidated total revenues for the second quarter of 2025 were $156.8 million compared with $182.2 million for the comparable period of 2024.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

• Pharmaceuticals: Revenue from products in the second quarter of 2025 was $40.7 million compared with $40.5 million in the second quarter of 2024, reflecting higher sales volumes in certain international operations partially offset by reduced sales in our Chilean subsidiary due to the impact of foreign currency and a mild winter cold and flu season.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

Revenue from sales of Rayaldee was $7.2 million for both the current and comparable period.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

Revenue from the transfer of intellectual property and other was $15.0 million in the second quarter of 2025 compared with $12.3 million in the 2024 period.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

• Diagnostics: Revenue from services in the second quarter of 2025 was $101.1 million compared with $129.4 million in the prior-year period, with the decrease primarily due to lower clinical test volume principally as a result of the sale of certain BioReference assets, partially offset by higher clinical test reimbursement rates.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

The second quarter of 2025 included revenue of $24.9 million and costs and expenses of $29.4 million from the oncology assets that are pending sale to Labcorp.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

AI analysis

Q2 2025 · reported Jul 31, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q2 2025

$156.8M

-13.9% -$25M vs year ago computed from stated figures

EX-99 · Jul 31, 2025

The quarter in charts

Revenue — quarterly

As stated

EX-99 · Jul 31, 2025 Statement values as stated in the release.

Headline figures

Metric	Q2 2025	Prior qtr	Year ago
Revenue	$156.8 million	—	$182.2 million

EX-99 · Jul 31, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

• OPKO’s Board of Directors authorized an additional $100 million for its common stock repurchase program, bringing total capacity to $200 million.

As of June 30, 2025, approximately $58.5 million of OPKO’s common stock has been repurchased under the program since its authorization in July 2024.

Company-stated claims

Feb 26, 2026

Forward-looking · double · capacity · by 2027

“This expansion is estimated to double EirGen's annual output capacity to approximately 1 billion units by 2027.”

10-K · Feb 26, 2026

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

• OPKO’s Board of Directors authorized an additional $100 million for its common stock repurchase program, bringing total capacity to $200 million.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

As of June 30, 2025, approximately $58.5 million of OPKO’s common stock has been repurchased under the program since its authorization in July 2024.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

Net loss during the second quarter of 2025 included $91.7 million of non-recurring expense related to the convertible note exchange that closed on April 1, 2025, including unamortized debt discount, debt issuance costs and inducement expense.

SEC original ↗Opko Health, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments.